Rice Hall James & Associates LLC Buys 88,711 Shares of Aspen Aerogels, Inc. (NYSE:ASPN)

Rice Hall James & Associates LLC grew its position in Aspen Aerogels, Inc. (NYSE:ASPN) by 19.9% during the third quarter, HoldingsChannel reports. The firm owned 535,113 shares of the construction company’s stock after buying an additional 88,711 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Aspen Aerogels were worth $14,817,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Point72 Hong Kong Ltd bought a new stake in Aspen Aerogels during the 2nd quarter valued at approximately $84,000. nVerses Capital LLC acquired a new stake in shares of Aspen Aerogels in the second quarter worth $95,000. Quent Capital LLC acquired a new stake in shares of Aspen Aerogels in the third quarter worth $118,000. Point72 DIFC Ltd bought a new position in Aspen Aerogels during the second quarter worth $121,000. Finally, Public Employees Retirement Association of Colorado acquired a new position in Aspen Aerogels during the 2nd quarter valued at $145,000. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other news, CFO Ricardo C. Rodriguez sold 32,465 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $30.14, for a total value of $978,495.10. Following the transaction, the chief financial officer now owns 20,790 shares of the company’s stock, valued at approximately $626,610.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Ricardo C. Rodriguez sold 32,465 shares of Aspen Aerogels stock in a transaction on Monday, August 26th. The stock was sold at an average price of $30.14, for a total transaction of $978,495.10. Following the completion of the sale, the chief financial officer now directly owns 20,790 shares of the company’s stock, valued at $626,610.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Donald R. Young sold 63,355 shares of the stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total value of $1,902,550.65. Following the completion of the transaction, the chief executive officer now directly owns 483,640 shares in the company, valued at $14,523,709.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Aspen Aerogels Trading Down 1.9 %

Shares of NYSE ASPN opened at $17.83 on Friday. Aspen Aerogels, Inc. has a 1-year low of $7.37 and a 1-year high of $33.15. The company has a 50-day moving average of $24.53 and a two-hundred day moving average of $24.51. The company has a market cap of $1.37 billion, a PE ratio of -1,783.00 and a beta of 2.16. The company has a current ratio of 3.46, a quick ratio of 2.82 and a debt-to-equity ratio of 0.23.

Aspen Aerogels (NYSE:ASPN) last posted its quarterly earnings data on Wednesday, August 7th. The construction company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.16. The firm had revenue of $117.80 million for the quarter, compared to the consensus estimate of $101.99 million. Aspen Aerogels had a return on equity of 0.74% and a net margin of 0.39%. The business’s revenue for the quarter was up 144.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.22) EPS. As a group, equities analysts expect that Aspen Aerogels, Inc. will post 0.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on ASPN shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Aspen Aerogels in a research report on Wednesday, October 16th. Barclays started coverage on Aspen Aerogels in a report on Tuesday, August 6th. They set an “overweight” rating and a $27.00 price objective on the stock. Benchmark reaffirmed a “buy” rating and issued a $14.00 target price on shares of Aspen Aerogels in a research report on Thursday, August 8th. TD Cowen lifted their target price on shares of Aspen Aerogels from $36.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, August 20th. Finally, Piper Sandler lowered their target price on shares of Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.40.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.